ALPN insider transaction filings
ALPINE IMMUNE SCIENCES, INC. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-05-20. Screen ALPN transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ALPN between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — ALPINE IMMUNE SCIENCES, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-05-20 | 4 | Hernday Natasha — Director | Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 17,500 (derivative) | EDGAR |
| 2024-05-20 | 4 | Drappa Jorn — Director | Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 17,500 (derivative) | EDGAR |
| 2024-05-20 | 4 | PENG STANFORD L — See Remarks | Disposition to issuer (D): 296,163 · Disposition to issuer (D): 48,000 · Disposition to issuer (D): 42,407 (derivative) · Disposition to issuer (D): 236,623 (derivative) · Disposition to issuer (D): 71,874 (derivative) · Disposition to issuer (D): 50,000 (derivative) · +5 more | EDGAR |
| 2024-05-20 | 4 | FUHS ULRICH MARTIN — Chief Accounting Officer | Disposition to issuer (D): 22,820 · Disposition to issuer (D): 7,300 · Disposition to issuer (D): 52,180 (derivative) · Disposition to issuer (D): 28,700 (derivative) · Disposition to issuer (D): 14,600 (derivative) | EDGAR |
| 2024-05-20 | 4 | DURAND REMY — Chief Business Officer | Disposition to issuer (D): 102,192 · Disposition to issuer (D): 31,200 · Disposition to issuer (D): 2,635 (derivative) · Disposition to issuer (D): 26,922 (derivative) · Disposition to issuer (D): 70,155 (derivative) · Disposition to issuer (D): 112,500 (derivative) · +2 more | EDGAR |
| 2024-05-20 | 4 | Peetz Christopher — Director | Disposition to issuer (D): 1,900 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 more | EDGAR |
| 2024-05-20 | 4 | Rickey James Paul — See Remarks | Disposition to issuer (D): 26,761 · Disposition to issuer (D): 31,200 · Disposition to issuer (D): 836 (derivative) · Disposition to issuer (D): 137 (derivative) · Disposition to issuer (D): 143 (derivative) · Disposition to issuer (D): 1,214 (derivative) · +4 more | EDGAR |
| 2024-05-20 | 4 | Cui Xiangmin — Director, 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. — 10% owner Decheng Capital Management III (Cayman), LLC — 10% owner Decheng Capital Global Healthcare Fund (Master), LP — 10% owner Decheng Capital Global Healthcare GP, LLC — 10% owner | Code (U): 6,582,380 · Code (U): 1,735,544 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 more | EDGAR |
| 2024-05-20 | 4 | Thompson Peter A. — Director | Code (U): 2,416,181 · Code (U): 264,315 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · +3 more | EDGAR |
| 2024-05-20 | 4 | Topper James N — Director | Code (U): 2,829,347 · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · +2 more | EDGAR |
| 2024-05-20 | 4 | GOLD MITCHELL — Executive Chairman and CEO, Director | Code (U): 2,627,157 · Disposition to issuer (D): 13,245 · Disposition to issuer (D): 96,000 · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 247,951 (derivative) · Disposition to issuer (D): 208,916 (derivative) · +6 more | EDGAR |
| 2024-05-20 | 4 | CONWAY ROBERT E — Director | Disposition to issuer (D): 50,000 · Disposition to issuer (D): 2,868 (derivative) · Disposition to issuer (D): 3,075 (derivative) · Disposition to issuer (D): 1,912 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 7,650 (derivative) · +5 more | EDGAR |
| 2024-05-20 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Code (U): 2,416,181 · Code (U): 264,315 | EDGAR |
| 2024-05-10 | 4 | PENG STANFORD L — See Remarks | Option exercise (M): 7,025 @ $13.20 · Option exercise (M): 3,126 @ $6.51 · Option exercise (M): 37,267 @ $0.65 · Option exercise (M): 161,492 @ $0.65 · Option exercise (M): 22,593 @ $11.31 · Option exercise (M): 26,912 @ $3.23 · +8 more | EDGAR |
| 2024-05-10 | 4 | DURAND REMY — Chief Business Officer | Option exercise (M): 9,845 @ $13.20 · Option exercise (M): 25,000 @ $6.51 · Option exercise (M): 12,365 @ $4.09 · Option exercise (M): 38,078 @ $3.23 · Option exercise (M): 10,000 @ $4.76 · Option exercise (M): 9,845 (derivative) @ $0 · +4 more | EDGAR |
| 2024-05-10 | 4 | FUHS ULRICH MARTIN — Chief Accounting Officer | Option exercise (M): 22,820 @ $12.07 · Option exercise (M): 22,820 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | GOLD MITCHELL — Executive Chairman and CEO, Director | Option exercise (M): 13,245 @ $7.55 · Option exercise (M): 13,245 (derivative) @ $0 | EDGAR |
| 2024-05-09 | 4 | Rickey James Paul — See Remarks | Option exercise (M): 1 @ $7.55 · Option exercise (M): 7,055 @ $13.20 · Option exercise (M): 857 @ $6.51 · Option exercise (M): 164 @ $11.31 · Option exercise (M): 18,286 @ $3.23 · Option exercise (M): 398 @ $5.02 · +6 more | EDGAR |
| 2024-04-29 | 4 | Topper James N — Director | Option exercise/expiry (X): 1,200,000 @ $0.00 · Sale (S): 19 @ $64.57 · Option exercise/expiry (X): 1,200,000 (derivative) @ $0 | EDGAR |
| 2024-01-29 | 4 | Rickey James Paul — See Remarks | Option exercise (M): 236 @ $6.51 · Sale (S): 236 @ $22 · Option exercise (M): 73,764 @ $6.51 · Sale (S): 73,764 @ $22.31 · Option exercise (M): 44,000 @ $11.31 · Sale (S): 44,000 @ $25 · +3 more | EDGAR |
| 2024-01-22 | 4 | Decheng Capital China Life Sciences USD Fund III, L.P. — 10% owner Decheng Capital Management III (Cayman), LLC — 10% owner | Option exercise/expiry (X): 1,234,636 @ $12.74 · Option exercise/expiry (X): 1,234,636 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Cui Xiangmin — Director, 10% owner | Option exercise/expiry (X): 1,234,636 @ $12.74 · Option exercise/expiry (X): 1,234,636 (derivative) @ $0 | EDGAR |
| 2024-01-16 | 4 | Thompson Peter A. — Director | Option exercise/expiry (X): 145,251 @ $12.74 · Option exercise/expiry (X): 145,251 (derivative) @ $0 | EDGAR |
| 2024-01-16 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Option exercise/expiry (X): 145,251 @ $12.74 · Option exercise/expiry (X): 145,251 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | PENG STANFORD L — See Remarks | Grant/award (A): 48,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Rickey James Paul — See Remarks | Grant/award (A): 31,200 @ $0 · Grant/award (A): 78,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | DURAND REMY — Chief Business Officer | Grant/award (A): 31,200 @ $0 · Grant/award (A): 78,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | GOLD MITCHELL — Executive Chairman and CEO, Director | Grant/award (A): 96,000 @ $0 · Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Hernday Natasha — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Drappa Jorn — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Peetz Christopher — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Cui Xiangmin — Director, 10% owner | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Thompson Peter A. — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Topper James N — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | CONWAY ROBERT E — Director | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Thompson Peter A. — Director | Sale (S): 162,576 @ $19.96 · Sale (S): 18,922 @ $19.96 · Sale (S): 26,872 @ $19.82 · Sale (S): 3,128 @ $19.82 · Sale (S): 1,195,683 @ $18.32 · Sale (S): 139,166 @ $18.32 | EDGAR |
| 2023-12-29 | 4 | GOLD MITCHELL — Executive Chairman and CEO, Director | Option exercise (M): 1,016 @ $0.65 · Sale (S): 1,016 @ $20.04 · Option exercise (M): 74,441 @ $12.74 · Tax withholding (F): 48,264 @ $19.65 · Option exercise (M): 1,016 (derivative) @ $0 · Option exercise (M): 74,441 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Sale (S): 162,576 @ $19.96 · Sale (S): 18,922 @ $19.96 · Sale (S): 26,872 @ $19.82 · Sale (S): 3,128 @ $19.82 · Sale (S): 1,195,683 @ $18.32 · Sale (S): 139,166 @ $18.32 | EDGAR |
| 2023-12-27 | 4 | GOLD MITCHELL — Executive Chairman and CEO, Director | Option exercise (M): 37,825 @ $0.45 · Sale (S): 37,825 @ $20.43 · Option exercise (M): 2,402 @ $0.45 · Option exercise (M): 22,084 @ $0.65 · Sale (S): 24,486 @ $20.22 · Option exercise (M): 29,573 @ $0.65 · +5 more | EDGAR |
| 2023-12-21 | 4 | Rickey James Paul — See Remarks | Option exercise (M): 15,213 @ $5.02 · Sale (S): 15,213 @ $19.21 · Option exercise (M): 15,213 (derivative) @ $0 | EDGAR |
| 2023-12-21 | 4 | GOLD MITCHELL — Executive Chairman and CEO, Director | Option exercise (M): 2,402 @ $0.45 · Sale (S): 2,402 @ $20.01 · Option exercise (M): 2,402 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Rickey James Paul — See Remarks | Option exercise (M): 11,600 @ $5.02 · Sale (S): 11,600 @ $19.00 · Option exercise (M): 45,387 @ $5.02 · Sale (S): 45,387 @ $19.09 · Option exercise (M): 1,800 @ $5.02 · Sale (S): 1,800 @ $19.00 · +3 more | EDGAR |
Recent 8-K events — ALPINE IMMUNE SCIENCES, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-05-20 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-03-18 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-07 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events | EDGAR |
| 2024-01-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALPN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →